RECEIVED CENTRAL FAX CENTER

FULBRIGHT & JAWORSKI L.L.P.

NOV 1 7 2004

A REGISTERED LIMITED LIABILITY PARTNERSHIP 666 FIFTH AVENUE, SIST FLOOR NEW YORK, NEW YORK 10103-3198 WWW.FULBRIGHT,COM

FACSIMILE TRANSMISSION

DATE: November 17, 2004

MATTER NUMBER:

01030

10109097

RECIPIENT(S):	FAX No.:	PHONE NO.:
Examiner Fozia M. Hamud Art Unit 1647 Commissioner for Patents	1571-273-0884 1703-872-9306	1571-272-0884

FROM:

Norman Hanson

FLOOR:

24

PHONE:

(212) 318-3168

FAX:

(212) 318-3400

RE:

U.S. Serial No. 10/026, 106 LUD 5752

Number of Pages Including Cover Page:

yicssage;			
		,	
``			
		•	

CAUTION - CONFIDENTIAL

THE INFORMATION CONTAINED IN THIS FACSIMILE IS CONFIDENTIAL AND MAY ALSO CONTAIN PRIVILEGED ATTORNEY-CLIENT INFORMATION OR WORK PRODUCT. THE INFORMATION IS INTENDED ONLY FOR THE USE OF THE INDIVIDUAL OR ENTITY TO WHOM IT IS ADDRESSED. IF YOU ARE NOT THE INTENDED RECIPIENT, OR THE EMPLOYEL OR AGEN'T RESPONSIBLE TO DELIVER IT TO THE INTENDED RECIPIENT, YOU ARE HEREBY NOTIFIED THAT ANY USE, DISSEMINATION, DISTRIBUTION OR COPYING OF THIS COMMUNICATION IS STRICTLY PROHIBITED. IF YOU HAVE RUCEIVED THE FACSIMILE IN ERROR, PLEASE IMMEDIATELY NOTIFY US BY TELEPHONE, AND RETURN THE ORIGINAL MESSAGE TO US AT THE ADDRESS ABOVE VIA

IF YOU DO NOT RECEIVE ALL O	F THE PAGES, PLEASE CALL
AT	
^^	AS SOON AS POSSIBLE.

NOV 17 2004 13:52 FR FULBRIGHT&JAWORSKI 212 318 3111 TO 0103010109097170 P.02/09

CENTRAL FAX CENTER

NOV 1 7 2004

LUD 5752 (10109097)

CERTIFICATE OF FACSIMILE TRANSMITTAL

I hereby certify that this correspondence is being transmitted via FACSIMILE pursuant to 37 CFR 1.8 to Group 1647, Examiner Fozia M. Hamud of the Commissioner for Patent at (571) 273-0884 and (703) 872-9306 on Nov. 17, 2004.

Sheila Murtha

(Name of Transmitter)

(Signature)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application of: Jean-Christophe RENAULD et al.

US Serial No.: 10/026,106

Group Art Unit: 1647

Filing Date: December 21, 2001

Examiner: Fozia M. HAMUD

For: ISOLATED CYTOKINE RECEPTOR LICR-2

SUBMISSION OF DECLARATION (37 C.F.R. § 1.116)

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Dear Sir:

In support of the patentability of this invention, applicants submit the accompanying declarations.

There are two declarations, but they are copies of the same declaration. The inventors are at different locations, hence the need for two.

25474217,1

LUD 5752 (10109097)

It is requested that this material be considered in this case.

Respectfully submitted,

Norman D. University

Norman D. Hanson
Registration No.: 30,946

FULBRIGHT & JAWORSKI L.L.P.

666 Fifth Avenue

New York, New York 10103

(212) 318-3000

(212) 318-3400 (Fax)

Attorneys for Applicant

Attachment: Letter Submission of Declaration

Received 11/16/2004 05:13 in 02:04 on line [3] for NH01030 Printed 11/16/2004 07:26 * Pg 2/7
16:NOV. 2004 10:15 7 212 LUDWIG INSTITUTEL FULBRIGHT JAWORSKI NO. 53057 P. 24 83/85

CENTRAL FAX CENTER

NOV 1 7 2004

LUD 5752 (10109097)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Applicant

Jean-Christophe RENAULD et al.

Scrial No.

10/026,106

Filed

December 21, 2001

For

11年12年20日日

おという

ISOLATED CYTOKINE RECEPTOR LICR-2

Art Unit

1647

Examiner

Fozia M. HAMUD

Commissioner for Patents P.O. Box 1450 Alexendria, VA 22313-1450

DECLARATION

The undersigned hereby declare as follows:

- We are the correctly named inventors of the above referenced application, and are fully familiar with it.
- We wish to elaborate on the experiments described in example 7 of this
 application, i.e., the ability of LICR-2 to activate STAT.
- 3. The cell line used in example 7 is known to express most of the STAT molecules.
- 4. Interleukin-29, or "IL-29", or "IFNL-1" is also known to be involved in the activation of STAT3. See WO 02/086087.
- We carried out experiments in which antiserum against LICR-2 was made and used. cDNA for LICR-2, as described in the application, was cloned into a vector,

<u> 1946</u>0793,1

RECEIVED TIME 28. OCT. 16:23

Received 11/16/2004 05:13 in 02:04 on Line (3) for NH01030 Printed 11/16/2004 07:26 * Pg 3/7
16: NOV. 2004 10:15: 13 21:LUDWIG INSTITUTENE FULERIGHT JANURSKI NO. 53054 P. 34 04/25

LUD 5752 (10100097)

i.e., pEF.BOS, pure, using standard methods, and recombinant constructs were transfected into murine mastocytoms cell line P815. These cell lines were then transplanted via injection into syngenic DBA/2 mice. In a first injection, 300,000 cells were used, in a subcutaneous footpad injection, which was followed about 40 days later, with 400,000 cells, via the same mode. Two weeks later, a third injection, of 2 million cells, was administered intraperitoneally.

- 6. Seta were collected, 22 days after the first injection, and then just before the third injection. Standard assays established that the antisers were specific for LICR-2.
- 7. The antisera were then used, in luciferase assays as described in example 7 where BW5147 cells were transfected with wild type, LICR-2 receptor. The cells were stimulated with IL-29 (25 ng/ml) and luciferase production was uprogulated by IL-29. In a parallel set of experiments, when the cells were preincubated with the LICR-2 antisera, no luciferase upregulation by IL-29 was seen.
- 8. The experiments in "7" were repeated, and the phosphorylation of STAT3 was measured, using standard assays. Phosphorylation of STAT3 is a prerequisite to its activation. No phosphorylation was observed in the presence of anti-LICR-2 serum.
- 9. These experiments lead to the conclusion that LICR-2 is in fact involved in STAT activation. STAT3 in particular.

35400793_1

を対応やの対抗な対応

とうとしたというないなっている

2

RECEIVED TIME 28. OCT. 16:23

Received 11/16/2004 05:13 in 02:04 on line [3] for NND1030 Printed 11/16/2004 07:26 * Pg 4/7
. 16: NOV. 2004 10:15 21:LUDWIG INSTITUTE 12 FULBRIENT JAMORSKI NO. 53054 P. 44 05/85

LUD 5782 (10109097)

10. We hereby declare that all statements made herein of our own knowledge are true, and that all statements made on information or belief are believed to be true; and further that these statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code, and that such willful false statements and the like so made may jeopardize the validity of this declaration, the subject application, or any patent issued thereon.

November 3, dec 4	Jean-Christophe RENAULD	
Date	Helmut FICKENSICHER	
November 3, 204	Laure DUMOUTIER	
November 9, 2004	E: K	

Simon HÓR

254(0)79).1

Date

3

RECEIVED TIME 28. OCT. 16:23

Received 11/16/2004 05:13 in 02:04 on line [3] for NK01030 Printed 11/16/2004 07:26 * Pg 5/7
V. 20042:10:16:09 212-0 DWIG INSTITUTE: FULBRIGHT JANORSKI NNO. 5305 P. 5 83/86 LUDWIG INSTITUTE 40 PECEIVED

CENTRAL FAX CENTER

NOV 1 7 2004

LUD 6752 (10109097)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In r. Applicant

Jean-Christophe RENAULD et al.

Serial No.

10/025,106

Filed

December 21, 2001

101

のでいる。日本の

ISOLATED CYTOKINE RECEPTOR LICR-2

Art Linft

1647

Examiner

Fozia M. HAMUD

Combussioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

DECLARATION

The undersigned hereby declare as follows:

- We are the correctly named inventors of the above referenced application, and are ١. fully familiar with it.
- 16 We wish to claborate on the experiments described in example 7 of this application, i.e., the ability of LICR-2 to activate STAT.
- The cell line used in example 7 is known to express most of the STAT molecules. 3.
- Intericultin-29, or "IL-29", or "IFNA-1" is also known to be involved in the activation of STAT3. See WO 02/086087.
- We carried out experiments in which antiserum against LICR-2 was made and 5. used. cDNA for LICR-2, as described in the application, was cloned into a vector,

25:50703.1

RECEIVE: TIME 28. OCT, 16:23

Received 11/16/2004 05:13 in 02:04 on Line [3] for NH01030 Printed 11/16/2004 07:26 * Pg 6/7
16: NOV. 20043-10:16:99 212_LUDWIG INSTITUTEL FULBRIGHT JAMORSKI NNO. 5305 p.P. 6

LUD 5762 (10109897)

i.e., pEF.BOS.puro, using standard methods, and recombinant constructs were transfected into murine mastocytoma cell line P815. These cell lines were then transplanted via injection into syngenic DBA/2 mice. In a first injection, 300,000 cells were used, in a subcutaneous footpad injection, which was followed about 40 days later, with 400,000 cells, via the same mode. Two weeks later, a third injection, of 2 million cells, was administered intraperstoneally.

- 5. Seta were collected, 22 days after the first injection, and then just before the third injection. Standard assays established that the antisem were specific for LICR-2.
- 7. The autisers were then used, in luciferase assays as described in example 7 where BW5147 cells were transfected with wild type, LICR-2 receptor. The cells were stimulated with IL-29 (25 ng/ml) and luciferase production was upregulated by IL-29. In a parallel set of experiments, when the cells were preincubated with the LICR-2 antisers, no luciferase upregulation by IL-29 was seen.
- 8. The experiments in "7" were repeated, and the phosphorylation of STAT3 was measured, using standard assays. Phosphorylation of STAT3 is a prerequisite to its activation. No phosphorylation was observed in the presence of anti-LICR-2 securit.
- 9. These experiments lead to the conclusion that LICR-2 is in fact involved in STAT activation. STAT3 in particular.

3,5400703.1

2

RECEIVEL TIME 28. OCT. 16:23



Received 71/16/2004 05:13 in 02:04 on line [3] for NHO1030 Printed 11/16/2004 07:26 * Pg 7/7
16: NOV. 20042-10:16.12 212-LUDWIG INSTITUTEL * FULBRIGHT JANORSKI NNO. 5305 P.P. 7
EUDWIG INSTITUTE3400

LUD 5752 (10109097)

10. We hereby declare that all statements made herein of our own knowledge are true, and that all statements made on information or belief are believed to be true; and further that these statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code, and that such willful false entements and the like so made may jeopardize the validity of this declaration, the subject application, or any patent issued thereon.

November 3, 2004	Renand
Date	Jean-Christopho RENAULD
November 9, 2004	Schunt Fichenscher
Date	Helmat FICKENSECHER
November 3, 204	
Date	Laure DUMOUTIER
Date	Simon HÖR

: Ju(4179) [

3

RECEIVED TIME 28 OCT. [6-23